DrugBiological
Ramucirumab clinical trials
Also written LY3009806, IMC-1121B and Cyramza.
- studies test it
- 119
- open now
- 16
- in phase 3
- 17
- first study started
- 2005
Keep track of what changes. Save the Ramucirumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
118 studies that test it; most in 2015 (13); 1 more planned to start later
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 4 |
| 2009 | 5 |
| 2010 | 9 |
| 2011 | 6 |
| 2012 | 5 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 13 |
| 2016 | 12 |
| 2017 | 5 |
| 2018 | 5 |
| 2019 | 12 |
| 2020 | 13 |
| 2021 | 7 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 7 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 37
- Phase 2
- 80
- Phase 3
- 17
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 62 · Other 57
Eli Lilly and Company (52) · SWOG Cancer Research Network (5) · Washington University School of Medicine (5) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (5) · Memorial Sloan Kettering Cancer Center (3) · Samsung Medical Center (2) · Yonsei University (2) · Sanofi (2)
Often tested with
Tested in the same studies.
Paclitaxel (22) · Pembrolizumab (9) · Irinotecan (8) · Docetaxel (6) · Nivolumab (5) · Albumin-Bound Paclitaxel (4) · Trastuzumab (4) · Carboplatin (4)
Studies
Open first, then newest update. How each study uses Ramucirumab is read from its arms, and is right about nine times in ten.
Testing it · 119
- Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel CancersRecruitingPhase 2SWOG Cancer Research NetworkNCT04205968Written as Ramucirumab
- Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaNot yet recruitingPhase 1Northwestern UniversityNCT07594548Written as Ramucirumab
- Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)RecruitingPhase 2SWOG Cancer Research NetworkNCT06031688Written as Ramucirumab
- A Platform Study in Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 1/2AstraZenecaNCT06996782Written as Ramucirumab
- A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic CancerRecruitingPhase 1Astellas Pharma Global Development, Inc.NCT05365581Written as Ramucirumab
- Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06445972Written as Ramucirumab
- Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal AdenocarcinomaNot yet recruitingPhase 3Gruppo Oncologico del Nord-OvestNCT07763171Written as Ramucirumab + Paclitaxel
- A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With CancerRecruitingPhase 2Eli Lilly and CompanyNCT05999994Written as Ramucirumab
- Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab MaintenanceRecruitingPhase 2Abramson Cancer Center at Penn MedicineNCT04332367Written as Ramucirumab
- Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)RecruitingPhase 2SWOG Cancer Research NetworkNCT05642572Written as Ramucirumab
- Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .RecruitingPhase 1/2National Health Research Institutes, TaiwanNCT05927857Written as Ramucirumab /Experimental
- Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal MetastasesRecruitingPhase 1City of Hope Medical CenterNCT06675136Written as Ramucirumab
- T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaRecruitingPhase 1/2Yonsei UniversityNCT05894824Written as T-Dxd(Trastuzmab deruxtecan), Ramucirumab
- A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver MetastasisNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06564298Written as Ramucirumab
- Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic TherapyRecruitingPhase 1Tianjin Medical University Cancer Institute and HospitalNCT05856864Written as Ramucirumab Injection
- Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)RecruitingPhase 2Masahiro TsuboiNCT04040361Written as Ramucirumab
- An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung CancerCompletedPhase 1Ono Pharmaceutical Co., Ltd.NCT06542731Written as Ramucirumab
- A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)Active, not recruitingPhase 3Eli Lilly and CompanyNCT02411448Written as Ramucirumab
- Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 BlockadeActive, not recruitingPhase 2Emory UniversityNCT04340882Written as Ramucirumab
- Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction CaCompletedPhase 1/2Baylor Research InstituteNCT04921904Written as Ramucirumab
See all 119 studies that test Ramucirumab →
Given in every arm · 32 — Ramucirumab is usual care beside what is tested
- Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialRecruitingPhase 2/3National Cancer Institute (NCI)NCT06203600Written as Ramucirumab
- A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2AstraZenecaNCT07098338Written as Ramucirumab
- Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingPhase 2/3SWOG Cancer Research NetworkNCT06616584Written as Ramucirumab
- A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric CancerRecruitingPhase 2Toray Industries, IncNCT06038578Written as Ramucirumab
- Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal AdenocarcinomasRecruitingPhase 2Gilead SciencesNCT07546812Written as Ramucirumab
- Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal AdenocarcinomaRecruitingPhase 2Canadian Cancer Trials GroupNCT06043427Written as Ramucirumab
- AB122 Platform StudyRecruitingPhase 1Taiho Pharmaceutical Co., Ltd.NCT04999761Written as Ramucirumab
- A Study of ASP1002 in Adults for Treatment of Solid TumorsRecruitingPhase 1Astellas Pharma Global Development, Inc.NCT05719558Written as Ramucirumab
- Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction CancerRecruitingPhase 2Academic and Community Cancer Research UnitedNCT04660760Written as Ramucirumab
- A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsCompletedPhase 1Toray Industries, IncNCT03872947Written as Ramucirumab
- Volrustomig Priming Regimens Exploratory Phase II Platform StudyActive, not recruitingPhase 2AstraZenecaNCT06448754Written as Ramucirumab
- Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL AdenocarcinomaActive, not recruitingPhase 2Harry H YoonNCT04069273Written as Ramucirumab
- Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative ChemotherapyCompletedPhase 2/3Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT03081143Written as Ramucirumab
- Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal CancersCompletedPhase 1Novartis PharmaceuticalsNCT03798626Written as Ramucirumab
- Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid TumorsActive, not recruitingPhase 1/2FBD Biologics LimitedNCT06771622Written as Ramucirumab
- Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2TerminatedPhase 1Elevation OncologyNCT05980416Written as Ramucirumab (CYRAMZA®)
- A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)Active, not recruitingPhase 2/3ALX Oncology Inc.NCT05002127Written as Ramucirumab
- A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)CompletedPhase 1ALX Oncology Inc.NCT03013218Written as Ramucirumab + Paclitaxel
- A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)TerminatedPhase 2Imugene LimitedNCT05311176Written as Ramucirumab plus Paclitaxel
- Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal CancerCompletedPhase 2/3Seagen Inc.NCT04499924Written as ramucirumab
Showing 20 of 32.
As the comparator · 11 — what is tested is compared with Ramucirumab
- A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung CancerNot yet recruitingPhase 3AbbVieNCT07821684Written as Ramucirumab
- SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing RegimenRecruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT06123494Written as Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
- Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT04310007Written as Ramucirumab
- AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2Active, not recruitingPhase 3AstraZenecaNCT06346392Written as Ramucirumab+ paclitaxel
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)TerminatedPhase 1/2Hoffmann-La RocheNCT03281369Written as Ramucirumab
- Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung CancerTerminatedPhase 1Genprex, Inc.NCT05062980Written as ramucirumab
- Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)Active, not recruitingPhase 3Daiichi SankyoNCT04704934Written as Ramucirumab
- Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)Active, not recruitingPhase 2/3SWOG Cancer Research NetworkNCT05096663Written as Ramucirumab
- Compare Pharmacokinetic, Safety, Tolerability and Immunogenicity of HLX12 and Ramucirumab in Healthy Male Adult SubjectsTerminatedPhase 1Shanghai Henlius BiotechNCT03863587Written as Cyramza (Ramucirumab)
- Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)WithdrawnPhase 2SWOG Cancer Research NetworkNCT04267913Written as Ramucirumab
- An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction AdenocarcinomaWithdrawnPhase 2Bristol-Myers SquibbNCT03704077Written as Ramucirumab
Codes
What other systems call Ramucirumab · ClinicalTrials.gg INT006871
- MeSH (NLM) D000096662RamucirumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) D99YVK4L0XRAMUCIRUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1535922Confirmed FDA, Wikidata
- Wikidata Q7290345ramucirumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C70792RamucirumabOne source FDA
- DrugBank DB05578One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000096662 | Ramucirumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | D99YVK4L0X | RAMUCIRUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1535922 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7290345 | ramucirumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C70792 | Ramucirumab | One source FDA |
| DrugBank | DB05578 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.